NCT03370536终止不适用
Panoramic ECGi to Guide Ablation of Non-Paroxysmal AF: Effect of Ibutilide on AF Source Location and Organization
Vivek Reddy1 个研究点 分布在 1 个国家目标入组 1 人开始时间: 2017年11月1日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 1
- 试验地点
- 1
- 主要终点
- Number of Participants Who no Longer Has Recurrent At/AF
研究概览
简要总结
This is a prospective, multi-center, non-randomized, un-blinded, observational trial.
详细描述
This prospective, multicenter observational study will examine the ability of ECGi mapping to
- Effect of Ibutilide on the number and size of the driver domains
- Effect of ablation of Ibutilide-organized driver domains
- Effect of PV isolation on driver domains
The researchers hypothesize that this approach will lead to successful arrhythmia control .
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •≥ 18 years of age.
- •° Symptomatic persistent AF refractory or intolerant to at least 1 class I or III antiarrhythmic medication Persistent AF - defined as Persistent: AF that is sustained > 7 days. Episodes of AF which are terminated by electrical or pharmacologic cardioversion after ≥ 48 hours of AF, but prior to 7 days, should also be classified as persistent AF episodes.
- •Planned to undergo first catheter ablation procedure ( prior atrial flutter typical is allowed)
- •Ability to understand the requirements of the study and sign the informed consent form.
- •Willingness to adhere to study restrictions and comply with all post-procedural follow-up requirements
- •Projected lifespan greater than 1 year
排除标准
- •They have baseline prolonged QT or renal failure precluding safe used of ibutilide
- •Rheumatic heart disease,
- •Current intra-cardiac thrombus,
- •History of MI or CABG within 6 weeks;
- •Class IV HF,
- •Unable to sign consent
- •Projected lifespan of < 1 year
- •Women known to be pregnant or to have positive beta-HCG.
- •Participation in another study that would interfere with this study.
- •Unstable Angina
- •Recent cerebral ischemic events
- •Contraindication to anticoagulation
- •Prior history of polymorphic ventricular tachycardia or torsades de pointes
研究组 & 干预措施
Patients with AF
Experimental
Patients with AF and planned to undergo first catheter procedure
干预措施: CardioInsight ECGI Mapping System (Device)
Patients with AF
Experimental
Patients with AF and planned to undergo first catheter procedure
干预措施: AF ablation (Procedure)
Patients with AF
Experimental
Patients with AF and planned to undergo first catheter procedure
干预措施: Ibutilide (Drug)
结局指标
主要结局
Number of Participants Who no Longer Has Recurrent At/AF
时间窗: at 12 months
Freedom from recurrent At/AF
次要结局
- Number of Drivers(Baseline)
- Size of Drivers(Baseline)
- Percent Change of Driver Regions(Baseline and 1 year)
- AF Termination Rate(post ablation inducibility of AF after 5 minutes of burst pacing)
- Total Procedure Time(within 24 hours after the procedure is completed the time is calculated)
研究者
Vivek Reddy
Professor
Icahn School of Medicine at Mount Sinai
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
Study of the RelayPro Thoracic Stent-Graft in Subjects With an Acute, Complicated Type B Aortic DissectionAortic Dissection Type BNCT03033043Bolton Medical56
已完成
不适用
An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With HBeAg-Positive or HBeAg-Negative Chronic Hepatitis BHepatitis B, ChronicNCT01734018Hoffmann-La Roche50
招募中
不适用
TEOSYAL RHA® 1 for the Correction of Moderate to Severe Tissue Volume Deficiency in the Infraorbital Region in Chinese AdultsInfraorbital HollowsNCT06749587Teoxane SA260
已完成
不适用
HAART Model 300 Annuloplasty RingAortic RegurgitationNCT01400841Biostable Science & Engineering18
招募中
不适用
Safety and Effectiveness of the Peripheral Balloon-Expandable Covered Stent System for Iliac Artery Stenosis/Occlusion. (SELECT)Peripheral Artery Disease (PAD)NCT06605209Zhejiang Zylox Medical Device Co., Ltd.130